Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (36 ops.)
Latest filing published 20 Aug 2026 for NEKTAR THERAPEUTICS, €12k.
Filing timeline
BuySaleJonathan Zalevsky
Insider track record
Disclosed buys
0
Disclosed sells
36
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Jonathan Zalevsky: trading record in brief
Jonathan Zalevsky, listed as senior executive, appears in our data through filings on Nektar Therapeutics shares, published by SEC (Form 4). The record holds 46 filings, for trades running from 1 October 2019 to 18 August 2026.
On the market, this insider has only sold: 36 sales, €3.6M in total. The rest of the record consists of 10 share grants. So far in 2026, the count stands at no purchases and 3 sales.
On 20 August 2026 came the latest disclosure, an open-market sale for €12k in Nektar Therapeutics. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Jonathan Zalevsky
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations29 total
186 shares@ US$71.980.0005% mcap0.9% of flowCommon StockSEC:0001193125-26-359588:0
180 shares@ US$73.000.8% of flowCommon StockSEC:0001193125-26-061886:0
3,867 shares@ US$35.679.0% of flowCommon StockSEC:0001193125-26-019843:0
6,250 shares0Common StockSEC:0001193125-25-331189:0
2,666 shares0Common StockSEC:0001193125-25-297855:0
793 shares@ US$32.4343.1% of flowCommon StockSEC:0000950170-25-113692:0
485 shares@ US$30.1043.1% of flowCommon StockSEC:0000950170-25-113130:0
725 shares@ US$26.59100.0% of flowCommon StockSEC:0000950170-25-110775:0
10,712 shares@ US$0.670.5% of flowCommon StockSEC:0000950170-25-075979:0
10,300 shares@ US$1.010.7% of flowCommon StockSEC:0000950170-25-025043:0
51,115 shares@ US$0.943.3% of flowCommon StockSEC:0000950170-24-139242:0
135,000 shares0Common StockSEC:0000950170-24-137545:0
7,785 shares@ US$1.010.5% of flowCommon StockSEC:0000950170-24-129463:0
6,866 shares@ US$1.280.6% of flowCommon StockSEC:0000950170-24-099354:0
7,355 shares@ US$1.750.9% of flowCommon StockSEC:0000950170-24-062645:0
9,014 shares@ US$0.680.4% of flowCommon StockSEC:0000950170-24-019045:0
9,646 shares@ US$0.490.3% of flowCommon StockSEC:0001209191-23-056184:0
9,703 shares@ US$0.780.5% of flowCommon StockSEC:0001209191-23-046462:0
9,791 shares@ US$0.720.5% of flowCommon StockSEC:0001209191-23-030448:0
10,484 shares@ US$3.002.1% of flowCommon StockSEC:0001209191-23-010956:0
13,460 shares@ US$3.573.3% of flowCommon StockSEC:0001209191-22-057968:0
73,716 shares@ US$4.6524.5% of flowCommon StockSEC:0001209191-22-046909:0
135,000 shares0Common StockSEC:0001209191-22-046489:0
23,950 shares0Common StockSEC:0001209191-22-029905:0
10,912 shares@ US$10.958.0% of flowCommon StockSEC:0001209191-22-011442:0
25 of 29 declarations
